47.97  0.06 (0.13%)		10-22 16:00
Open: 47.96 High: 48 Volume: 2,387,791		Pre. Close: 47.91 Low: 47.94 Market Cap: 1,232(M)

Short term
Mid term
Targets	6-month :	56.37	1-year :	65.85
Resists	First :	48.27	Second :	56.37
Pivot price	47.89
Supports	First :	47.89	Second :	47.66
MAs	MA(5) :	47.92	MA(20) :	47.88
	MA(100) :	29.01	MA(250) :	22.68
MACD	MACD :	2	Signal :	2.7
%K %D	K(14,3) :	85.8	D(3) :	68.1
RSI	RSI(14): 89.5
52-week	High :	48.27	Low :	11.56

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TRML ] has closed Bollinger Bands are 98.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	48.04 - 48.28	48.28 - 48.48
Low:	47.37 - 47.65	47.65 - 47.88
Close:	47.56 - 47.98	47.98 - 48.35

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Fri, 03 Oct 2025
Tourmaline Bio, Inc. (TRML) Stock Analysis: Is Its Biotech Potential Worth the $1.23 Billion Market Cap? - DirectorsTalk Interviews

Tue, 09 Sep 2025
Novartis to acquire US-based Tourmaline Bio for $1.4 bln - Investing.com

Tue, 09 Sep 2025
Tourmaline Bio Agrees To Be Acquired By Novartis In $1.4 Bln Deal; Stock Up - Nasdaq

Tue, 09 Sep 2025
Tourmaline Bio To Be Acquired By Novartis AG For $1.4 Billion - citybiz

Tue, 09 Sep 2025
Novartis Inks $1.4 Billion Deal. Why It Just 'Makes Sense.' - Investor's Business Daily

Tue, 09 Sep 2025
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	26 (M)
Shares Float	13 (M)
Held by Insiders	15.4 (%)
Held by Institutions	89.2 (%)
Shares Short	983 (K)
Shares Short P.Month	2,650 (K)

EPS	-3.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	10.09
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-20.9 %
Return on Equity (ttm)	-29.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.99
Qtrly Earnings Growth	0 %
Operating Cash Flow	-86 (M)
Levered Free Cash Flow	-53 (M)

PE Ratio	-13.95
PEG Ratio	0
Price to Book value	4.75
Price to Sales	0
Price to Cash Flow	-14.29

Dividend	15.11
Forward Dividend	0
Dividend Yield	31.5%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.